EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001 Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...

Epstein-Barr Virus Market Likely to Exhibit Substantial Growth by 2032, Examines DelveInsight | Key Players in the Market - Viracta, Atara, AlloVir, ModernaTX, Immunitas, Schrödinger, VelosBio, Takeda, Gilead, Merck New York, USA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Epstein-Barr Virus Market Likely to Exhibit Substantial Growth by 2032, Examines DelveInsight | Key Players in the Market - Viracta, Atara, AlloVir,...

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results...

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results...

EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases Presentation at the World Vaccine Congress 2023EBV-infections associated with many cancers and multiple sclerosis Munich, Germany, April 3, 2023 – EBViously, a start-up developing novel vaccines...